secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2023-04-25T23:59:59+00:00
Accession:  0001493152-23-013426
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Interpace Biosciences appoints Christopher McCarthy as Principal Financial Officer
--------------------------------------------------------------------------------

- Christopher McCarthy, 31, appointed Principal Financial Officer effective April 21, 2023.
- McCarthy had served as VP of Finance and Enterprise Systems since August 2022.
- Prior roles at Interpace: Senior Director of Operations Finance (Aug 2020-Aug 2022) and Senior Financial Analyst (June 2019-Aug 2020).
- Before Interpace, he was Senior Financial Systems Analyst at Simon & Schuster (Jan 2016-June 2019).
- No family relationships or related party transactions disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315223013426/0001493152-23-013426-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315223013426/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-013426

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer